Loomis Sayles & CO L P Myriad Genetics Inc Transaction History
Loomis Sayles & CO L P
- $76.2 Billion
- Q3 2024
A detailed history of Loomis Sayles & CO L P transactions in Myriad Genetics Inc stock. As of the latest transaction made, Loomis Sayles & CO L P holds 2,189,601 shares of MYGN stock, worth $33.5 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
2,189,601
Previous 863,104
153.69%
Holding current value
$33.5 Million
Previous $21.1 Million
184.07%
% of portfolio
0.08%
Previous 0.03%
Shares
10 transactions
Others Institutions Holding MYGN
# of Institutions
253Shares Held
90.9MCall Options Held
100KPut Options Held
34K-
Black Rock Inc. New York, NY15.2MShares$232 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$158 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.72MShares$103 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$79.2 Million0.07% of portfolio
-
State Street Corp Boston, MA4.7MShares$72 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.23B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...